 
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Journal of the New Zealand Medical Association, 05-March-2010, Vol 123 No 1310 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
[full text] [PDF] Standardisation of reporting haemoglobin A1c: adoption of the New Zealand Society for the Study of Diabetes (NZSSD) position statement
Chris Florkowski, Michael Crooke
AbstractThe haemoglobin A1c (HbA1c) assay has become the gold-standard measurement of chronic glycaemia, providing an integrated index of glycaemic control over the preceding 2–3 months and with elevated values related to increased risk of microvascular and probably macrovascular complications of diabetes mellitus. The present article describes some of the issues related to HbA1c and how global initiatives have addressed the non-standardisation of this assay, culminating in a major international consensus statement, with implications for the way HbA1c is reported world-wide from clinical laboratories.
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other journals |
|